Palbociclib

Product introduction:

Pabcilib is an inhibitor of cyclin dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4 / 6 are downstream of the signal pathway leading to cell proliferation. In vitro, pabcilib estrogen receptor (ER) - positive breast cancer cell lines reduce cell proliferation by blocking the progression of cells from G1 to S phase of cell cycle. Compared with each drug alone, the combined treatment of pabcilib and anti estrogen resulted in decreased phosphorylation of retinoblastoma protein (RB), decreased E2F expression and signal and prevented increased growth. In vitro treatment of ER positive breast cancer cell lines with pabcilib and anti estrogen resulted in increased cell senescence, which lasted up to 6 days after drug removal.

Synonymous：	Pabcilib
CAS：	571190-30-2
Molecular Formula：	C₂₄H₂₉N₇O₂
Molecular Weight：	447.53
Appearance：	White to beige powder
Storage：	Closed storage at room temperature
Category：	Tumor drugs

Properties

Pabcicilib is an inhibitor of cyclin dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4 / 6 are downstream signaling pathways leading to cell proliferation. In vitro, the proliferation of ER positive breast cancer cells was inhibited by blocking the progression from G1 to S phase. Compared with the treatment of each drug alone, the combination of pabacib and anti estrogen resulted in decreased phosphorylation of retinoblastoma protein (RB), decreased E2F expression and signal, and prevented growth. In vitro treatment of ER positive breast cancer cell lines with combination of pabacib and anti estrogen resulted in increased cell senescence, which lasted up to 6 days after drug removal.

b

Send Email

Palbociclib

Product introduction: